The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Market Size Trajectory Of The Angiotensin Receptor Blockers (ARBs) Market From 2026 To 2030?
The market size for angiotensin receptor blockers (arbs) has experienced consistent growth in recent years. It is projected to increase from $8.78 billion in 2025 to $9.18 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.6%. The historical expansion can be attributed to factors such as the rising prevalence of hypertension, increasing public awareness of cardiovascular diseases, the expansion of hospital networks, the introduction of new arb molecules, and escalating research into kidney disease treatments.
The market for angiotensin receptor blockers (ARBs) is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $11.02 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.7%. Factors contributing to this growth during the forecast period include an aging demographic, increasing demand for individualized medical treatments, innovations in drug delivery technologies, rising healthcare spending, and the proliferation of specialty medical facilities. Key developments expected within this timeframe encompass personalized approaches to hypertension management, an increase in therapies for chronic kidney disease, broader cardiovascular disease treatment options, greater uptake of oral ARB formulations, and a surge in prescriptions from hospitals and specialty clinics.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp
Which Major Drivers Are Influencing The Expansion Of The Angiotensin Receptor Blockers (ARBs) Market?
The growing occurrence of cardiovascular diseases is anticipated to boost the expansion of the angiotensin receptor blockers market in the coming years. Cardiovascular disease (CVD) refers to any ailment impacting the heart or blood vessels, often linked to the accumulation of fatty deposits in arteries (atherosclerosis) and a heightened risk of blood clots. Angiotensin receptor blockers reduce blood pressure and enhance the heart’s pumping efficiency by facilitating the relaxation of veins and arteries, thereby decreasing the likelihood of cardiovascular disease. For example, data from January 2024, provided by the American Heart Association, a US-based non-profit organization, indicated that the age-adjusted mortality rate from cardiovascular disease rose to 233.3 per 100,000 in 2024, an increase of 4.0% from 224.4 per 100,000 in 2023. Consequently, the rising prevalence of cardiovascular diseases is fueling the expansion of the angiotensin receptor blockers market.
Which Segment Classifications Are Used In The Angiotensin Receptor Blockers (ARBs) Market Segment Analysis?
The angiotensin receptor blockers (arbs) market covered in this report is segmented –
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
Which Trends Are Contributing To Changes In The Angiotensin Receptor Blockers (ARBs) Market?
Leading companies in the angiotensin receptor blocker market are actively developing advanced products, such as angiotensin receptor neprilysin inhibitors, to broaden treatment options and enhance patient outcomes for cardiovascular conditions. Angiotensin receptor neprilysin inhibitors (ARNIs) represent a category of drugs employed in managing heart failure. For instance, in January 2023, Glenmark Pharmaceuticals, an India-based pharmaceutical company, introduced sacubitril + valsartan tablets, specifically tailored for the treatment of heart failure, particularly heart failure with reduced ejection fraction (HFrEF). This combination medication is classified as an ARNI (angiotensin receptor neprilysin inhibitor). Sacubitril functions by strengthening the natriuretic peptide (NP) system, which helps to relieve fluid retention and encourage blood vessel widening, while valsartan works by obstructing the renin-angiotensin system (RAS) to reduce blood pressure and decrease the heart’s effort. Collectively, they are effective in improving heart failure symptoms, lessening the risk of cardiovascular mortality, and reducing the chances of hospitalization related to heart failure. These are commercially sold under the brand name Sacu V.
Which Firms Are Contributing To The Angiotensin Receptor Blockers (ARBs) Market Ecosystem?
Major companies operating in the angiotensin receptor blockers (arbs) market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, AbbVie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma, Thermo Fisher Scientific.
Get The Full Angiotensin Receptor Blockers (ARBs) Market Report:
Which Region Represents The Largest Share Of The Angiotensin Receptor Blockers (ARBs) Market?
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2025. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Angiotensin Receptor Blockers (ARBs) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Angiotensin Receptor Blockers (ARBs) Market 2026, By The Business Research Company
Angiotensin Receptor Blockers Arbs Market Report 2026
Anti Hypertensive Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report
Angina Pectoris Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model